5 recruiting, 4 not yet recruiting, 4 unknown, 3 completed. 4 Not applicable, 3 Phase 4, 1 Early Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Not yet recruiting 2, Recruiting 2 |
| Phase 4 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Dual Antiplatelet Therapy: new trials by email Literature Review of Dual Antiplatelet Therapy trials Research Report on Dual Antiplatelet Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TOP-CABG Trial: Follow-up Extension (TOP-CABG FE) Coronary Artery Disease, Coronary Artery Bypass Grafting | Not yet recruiting | China National Center for Cardiovascular Diseases | 2290 | 2026-10-15 | 2026-10-13 | |
| Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy) - Coronary Artery Disease, Coronary Artery Bypass Grafting | Not applicable | Not yet recruiting | Kexiang Liu, MD | 300 | 2026-05-01 | 2026-04-24 |
| Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38) Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT) - Coronary Disease, Heart Diseases | Not applicable | Recruiting | Fondazione Ricerca e Innovazione Cardiovascolare ETS | 576 | 2026-01-10 | 2026-01-22 |
| 24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial 24 Months DAPT, 12 Months DAPT - Elevated Lipoprotein(a) Level, Coronary Artery Disease | Not applicable | Recruiting | China National Center for Cardiovascular Diseases | 3300 | 2025-06-20 | 2025-07-18 |
| Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients DAPT de-escalation - Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI) | Not applicable | Not yet recruiting | University Medical Center Ho Chi Minh City (UMC) | 3566 | 2025-03-01 | 2024-10-18 |
| OCT or Angiography Guided De-escalation of DAPT OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation - Optical Coherence Tomography, Dual Antiplatelet Therapy | Early Phase 1 | Not yet recruiting | Shenyang Northern Hospital | 80 | 2024-04-01 | 2024-04-01 |
| De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS P2Y12 inhibitor de-escalation - Dual Antiplatelet Therapy, Acute Coronary Syndrome | Phase 3 | Unknown | Azienda Ospedaliera Universitaria Policlinico "G. Martino" | 200 | 2023-06-12 | 2023-08-23 |
| Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting De-escalated Dual Antiplatelet Therapy, Dual Antiplatelet Therapy - Coronary Artery Disease, Coronary Artery Bypass Grafting | Phase 4 | Completed | China National Center for Cardiovascular Diseases | 2300 | 2023-02-14 | 2025-08-27 |
| Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients Prasugrel based short DAPT, Prasugrel based standard DAPT, OCT guided revascularization - ST Elevated Myocardial Infarction, Dual Antiplatelet Therapy | Phase 4 | Recruiting | Research Maatschap Cardiologen Rotterdam Zuid | 1656 | 2022-07-22 | 2026-07-02 |
| Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure Coronary Artery Disease, Percutaneous Coronary Intervention | Recruiting | Genoss Co., Ltd. | 1000 | 2022-05-13 | 2025-02-21 | |
| Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease Percutaneous Coronary Intervention, Dual Antiplatelet Therapy | Recruiting | Genoss Co., Ltd. | 1000 | 2021-08-18 | 2025-02-21 | |
| Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease Clopidogrel, Aspirin, Atorvastatin - Acute Stroke, Dual Antiplatelet Therapy | Phase 2 | Completed | Chang Gung Memorial Hospital | 376 | 2021-03-23 | 2025-03-26 |
| Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease 1 month DAPT, 6 months DAPT - Coronary Disease, Drug Eluting Stent | Phase 4 | Unknown | Shanghai MicroPort Medical (Group) Co., Ltd. | 1720 | 2019-06-01 | 2020-09-09 |
| Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration prolonged DAPT - Coronary Artery Disease, Percutaneous Coronary Intervention | Unknown | Seoul National University Hospital | 16000 | 2017-03-01 | 2018-02-22 | |
| Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial Platelet reactivity testing - Dual Antiplatelet Therapy, Platelet Reactivity | Unknown | Rabin Medical Center | 60 | 2016-09-01 | 2016-06-21 | |
| Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition Percutaneous Coronary Intervention, Dual Antiplatelet Therapy | Completed | Icahn School of Medicine at Mount Sinai | 318 | 2012-03-01 | 2015-12-23 |
Coronary Artery Disease (8) · Hemorrhage (3) · Myocardial Ischemia (3) · Acute Coronary Syndrome (2) · Coronary Disease (2) · Myocardial Infarction (2) · ST Elevation Myocardial Infarction (2) · Angina Pectoris (1) · Arterial Occlusive Diseases (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Coronary Stenosis (1) · Heart Diseases (1) · Stroke (1) · Vascular Diseases (1)
Cardiovascular Diseases (11) · Vascular Diseases (11) · Heart Diseases (10) · Arteriosclerosis (8) · Myocardial Ischemia (8) · Arterial Occlusive Diseases (7) · Coronary Disease (7) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Infarction (4) · Ischemia (4) · Necrosis (4) · Myocardial Infarction (2) · Brain Diseases (1) · Central Nervous System Diseases (1)
2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine (3) · Aspirin (2) · Atorvastatin (1) · Clopidogrel (1) · Rosuvastatin Calcium (1) · Ticagrelor (1)
China National Center for Cardiovascular Diseases (3) · Genoss Co., Ltd. (2) · Azienda Ospedaliera Universitaria Policlinico "G. Martino" (1) · Chang Gung Memorial Hospital (1) · Fondazione Ricerca e Innovazione Cardiovascolare ETS (1) · Icahn School of Medicine at Mount Sinai (1) · Kexiang Liu, MD (1) · Rabin Medical Center (1) · Research Maatschap Cardiologen Rotterdam Zuid (1) · Seoul National University Hospital (1) · Shanghai MicroPort Medical (Group) Co., Ltd. (1) · Shenyang Northern Hospital (1) · University Medical Center Ho Chi Minh City (UMC) (1)
China (5) · Italy (3) · South Korea (3) · Belgium (1) · Czechia (1) · Germany (1) · Israel (1) · Netherlands (1) · Serbia (1) · Taiwan (1) · United States (1) · Vietnam (1)
Eli Lev, MD (1) · George Dangas, MD (1) · Guy Witberg, MD (1) · Kai Chen (1) · Kefei Dou, MD, PhD (1) · Kongyong Cui, MD, PhD (1) · Qing Chu, PhD (1) · Shengshou Hu, MD (1) · Valeria Paradies, MD, PhD (1) · Xin Yuan, PhD (1) · Yaling Han (1) · Yaling Han, MD (1)
PMID 30597509, PMID 34503738, PMID 34503739, PMID 34836908, PMID 37385747, PMID 39314261, PMID 40375771, PMID 40726739, PMID 42120081, PMID 42567765